구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 3개 · Data Tier에서 열림
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | enfortumab vedotin (Padcev, ASG-22ME, enfortumab-vedotin-ejfv) Astellas / Pfizer (Seagen)·Nectin-4 201 trials·t½ ADC ~3.4 days; free MMAE ~2.4 days | datopotamab deruxtecan (Datroway, DS-1062, Dato-DXd, datopotamab-deruxtecan-dlnk) Daiichi Sankyo / AstraZeneca·TROP2 50 trials·t½ ADC ~6 days; released DXd cleared rapidly | mirvetuximab soravtansine (Elahere, IMGN853, mirvetuximab-soravtansine-gynx) AbbVie / ImmunoGen·FRα (folate receptor alpha) 32 trials·t½ ADC ~4.8 days |
|---|---|---|---|
Overview Program | Padcev (enfortumab vedotin) | Datroway (datopotamab deruxtecan) | Elahere (mirvetuximab soravtansine) |
Overview Company | Astellas / Pfizer (Seagen) | Daiichi Sankyo / AstraZeneca | AbbVie / ImmunoGen |
Overview Modality | ADC | ADC | ADC |
Overview Target | Nectin-4 | TROP2 | FRα (folate receptor alpha) |
Overview Indication | Locally advanced or metastatic urothelial carcinoma | HR+/HER2− breast cancer; EGFR-mutated non-small cell lung cancer | FRα-positive platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer |
Overview Phase | APPROVED | APPROVED | APPROVED |
Overview Status | APPROVED | APPROVED | APPROVED |
Overview Content status | Curated Core | Curated Core | Curated Core |
Overview Data Confidence | Data Confidence · High | Data Confidence · High | Data Confidence · High |
Overview Development Signal | Development Signal · Established | Development Signal · Established | Development Signal · Established |
Overview Approval status | FDA approved | FDA approved | FDA approved |
Positioning Key differentiator | Nectin-4 is near-uniformly expressed in urothelial carcinoma, giving an unusually clean tumor-selective target in that tissue. | Same DXd chemistry that made Enhertu work, aimed at TROP2 — high plasma stability with a short-half-life payload to limit systemic exposure. | FRα is overexpressed in ovarian cancer but sparse in normal tissue, and the label requires IHC-confirmed expression. |
Positioning Known limitation | Nectin-4 loss, MMAE efflux, and tubulin alterations. | TROP2 loss, SLFN11 status, and topoisomerase I pathway adaptation. | FRα downregulation and multidrug-resistance transporter upregulation. |
Positioning Development positioning | 1L standard of care in urothelial carcinoma with pembrolizumab. | Second TROP2 ADC to market; competes with Trodelvy on tolerability rather than novelty of target. | Only FRα-directed ADC approved in ovarian cancer. |
Technology Payload | MMAE (monomethyl auristatin E, tubulin inhibitor) | DXd (exatecan derivative, topoisomerase I inhibitor) | DM4 (maytansinoid, tubulin inhibitor) |
Technology Linker | Protease-cleavable mc-vc-PAB, DAR ~3.8 | Tetrapeptide-based cleavable maleimide linker, DAR ~4 | Cleavable sulfo-SPDB disulfide, DAR ~3.5 |
Technology DAR | DAR 3.8 | DAR 4 | DAR 3.5 |
MoA Mechanism | Binds Nectin-4 on urothelial tumor cells, internalizes, and releases MMAE after cathepsin B cleavage; microtubule disruption arrests mitosis and triggers apoptosis. | Anti-TROP2 antibody delivers DXd intracellularly after lysosomal linker cleavage; topoisomerase I inhibition drives DNA damage, with membrane-permeable payload producing a bystander effect. | Binds FRα, internalizes via receptor-mediated endocytosis, and releases DM4 after disulfide reduction; tubulin disruption causes mitotic arrest, with lipophilic S-methyl-DM4 giving bystander activity. |
MoA Biomarker | Nectin-4 expression is high in urothelial carcinoma; no companion diagnostic required. | TROP2 expression is not a required companion diagnostic; quantitative continuous scoring (QCS) is investigational. | FRα IHC (VENTANA FOLR1 RxDx), PS2+ scoring with ≥75% of tumor cells staining. |
PK/PD Half-life | ADC ~3.4 days; free MMAE ~2.4 days | ADC ~6 days; released DXd cleared rapidly | ADC ~4.8 days |
PK/PD Species | Cynomolgus monkey, ORR, PFS, OS | Cynomolgus monkey, Mouse, PFS by BICR, ctDNA and TROP2 QCS exploratory | Cynomolgus monkey, Human, ORR, PFS, OS in FRα-high population |
PK/PD Animal (cat.) | Human, NHP, In vitro | Human, Mouse, NHP, In vitro | Human, NHP, In vitro |
PK/PD Experiment | Pharmacokinetic | pd | PD |
Toxicology Species | Cynomolgus monkey, Mouse, Rat | Mouse, Rat, Hamster | Mouse, Rat, Human |
Toxicology Major finding | Boxed warning for serious skin reactions including SJS/TEN. Hyperglycemia, peripheral neuropathy, ocular surface toxicity, and pneumonitis also require monitoring. | Stomatitis, dry eye and keratitis, nausea, and alopecia. Interstitial lung disease is a class warning for DXd conjugates and requires prompt steroid intervention. | Boxed warning for ocular toxicity — keratopathy, blurred vision, and dry eye. Peripheral neuropathy, nausea, and fatigue are also common. |
Toxicology CRS | N/A | N/A | N/A |
Clinical Safety signal | Boxed warning for serious skin reactions including SJS/TEN. Hyperglycemia, peripheral neuropathy, ocular surface toxicity, and pneumonitis also require monitoring. | Stomatitis, dry eye and keratitis, nausea, and alopecia. Interstitial lung disease is a class warning for DXd conjugates and requires prompt steroid intervention. | Boxed warning for ocular toxicity — keratopathy, blurred vision, and dry eye. Peripheral neuropathy, nausea, and fatigue are also common. |
Clinical Selected reported efficacy | ORR 67.7% | ORR 79% | ORR 52% |
Clinical Reported ORR | 67.7% (EV + pembrolizumab) | 74% | 100% |
Clinical Reported PFS | 12.5 mo vs 6.3 mo (chemo) | 4.4 | 13.49 |
Clinical Reported OS | 31.5 mo vs 16.1 mo (chemo) | 12.9 | — |
Clinical Result source | EV-302 / KEYNOTE-A39 (NCT04223856) | ClinicalTrials.gov NCT04656652 | ClinicalTrials.gov NCT02606305 |
Clinical Program phase | APPROVED | APPROVED | APPROVED |
Clinical Trial activity | No active/completed counts | No active/completed counts | No active/completed counts |
Clinical Trial ref | NCT04223856 | NCT04656652 | NCT02606305 |
Preclinical Animal (cat.) | Human, Mouse, In vitro | Mouse, In vitro | Human, Mouse, Rat, In vitro |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 3개 · Data Tier에서 열림
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | enfortumab vedotin (Padcev, ASG-22ME, enfortumab-vedotin-ejfv) Astellas / Pfizer (Seagen)·Nectin-4 201 trials·t½ ADC ~3.4 days; free MMAE ~2.4 days | datopotamab deruxtecan (Datroway, DS-1062, Dato-DXd, datopotamab-deruxtecan-dlnk) Daiichi Sankyo / AstraZeneca·TROP2 50 trials·t½ ADC ~6 days; released DXd cleared rapidly | mirvetuximab soravtansine (Elahere, IMGN853, mirvetuximab-soravtansine-gynx) AbbVie / ImmunoGen·FRα (folate receptor alpha) 32 trials·t½ ADC ~4.8 days |
|---|---|---|---|
Overview Program | Padcev (enfortumab vedotin) | Datroway (datopotamab deruxtecan) | Elahere (mirvetuximab soravtansine) |
Overview Company | Astellas / Pfizer (Seagen) | Daiichi Sankyo / AstraZeneca | AbbVie / ImmunoGen |
Overview Modality | ADC | ADC | ADC |
Overview Target | Nectin-4 | TROP2 | FRα (folate receptor alpha) |
Overview Indication | Locally advanced or metastatic urothelial carcinoma | HR+/HER2− breast cancer; EGFR-mutated non-small cell lung cancer | FRα-positive platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer |
Overview Phase | APPROVED | APPROVED | APPROVED |
Overview Status | APPROVED | APPROVED | APPROVED |
Overview Content status | Curated Core | Curated Core | Curated Core |
Overview Data Confidence | Data Confidence · High | Data Confidence · High | Data Confidence · High |
Overview Development Signal | Development Signal · Established | Development Signal · Established | Development Signal · Established |
Overview Approval status | FDA approved | FDA approved | FDA approved |
Positioning Key differentiator | Nectin-4 is near-uniformly expressed in urothelial carcinoma, giving an unusually clean tumor-selective target in that tissue. | Same DXd chemistry that made Enhertu work, aimed at TROP2 — high plasma stability with a short-half-life payload to limit systemic exposure. | FRα is overexpressed in ovarian cancer but sparse in normal tissue, and the label requires IHC-confirmed expression. |
Positioning Known limitation | Nectin-4 loss, MMAE efflux, and tubulin alterations. | TROP2 loss, SLFN11 status, and topoisomerase I pathway adaptation. | FRα downregulation and multidrug-resistance transporter upregulation. |
Positioning Development positioning | 1L standard of care in urothelial carcinoma with pembrolizumab. | Second TROP2 ADC to market; competes with Trodelvy on tolerability rather than novelty of target. | Only FRα-directed ADC approved in ovarian cancer. |
Technology Payload | MMAE (monomethyl auristatin E, tubulin inhibitor) | DXd (exatecan derivative, topoisomerase I inhibitor) | DM4 (maytansinoid, tubulin inhibitor) |
Technology Linker | Protease-cleavable mc-vc-PAB, DAR ~3.8 | Tetrapeptide-based cleavable maleimide linker, DAR ~4 | Cleavable sulfo-SPDB disulfide, DAR ~3.5 |
Technology DAR | DAR 3.8 | DAR 4 | DAR 3.5 |
MoA Mechanism | Binds Nectin-4 on urothelial tumor cells, internalizes, and releases MMAE after cathepsin B cleavage; microtubule disruption arrests mitosis and triggers apoptosis. | Anti-TROP2 antibody delivers DXd intracellularly after lysosomal linker cleavage; topoisomerase I inhibition drives DNA damage, with membrane-permeable payload producing a bystander effect. | Binds FRα, internalizes via receptor-mediated endocytosis, and releases DM4 after disulfide reduction; tubulin disruption causes mitotic arrest, with lipophilic S-methyl-DM4 giving bystander activity. |
MoA Biomarker | Nectin-4 expression is high in urothelial carcinoma; no companion diagnostic required. | TROP2 expression is not a required companion diagnostic; quantitative continuous scoring (QCS) is investigational. | FRα IHC (VENTANA FOLR1 RxDx), PS2+ scoring with ≥75% of tumor cells staining. |
PK/PD Half-life | ADC ~3.4 days; free MMAE ~2.4 days | ADC ~6 days; released DXd cleared rapidly | ADC ~4.8 days |
PK/PD Species | Cynomolgus monkey, ORR, PFS, OS | Cynomolgus monkey, Mouse, PFS by BICR, ctDNA and TROP2 QCS exploratory | Cynomolgus monkey, Human, ORR, PFS, OS in FRα-high population |
PK/PD Animal (cat.) | Human, NHP, In vitro | Human, Mouse, NHP, In vitro | Human, NHP, In vitro |
PK/PD Experiment | Pharmacokinetic | pd | PD |
Toxicology Species | Cynomolgus monkey, Mouse, Rat | Mouse, Rat, Hamster | Mouse, Rat, Human |
Toxicology Major finding | Boxed warning for serious skin reactions including SJS/TEN. Hyperglycemia, peripheral neuropathy, ocular surface toxicity, and pneumonitis also require monitoring. | Stomatitis, dry eye and keratitis, nausea, and alopecia. Interstitial lung disease is a class warning for DXd conjugates and requires prompt steroid intervention. | Boxed warning for ocular toxicity — keratopathy, blurred vision, and dry eye. Peripheral neuropathy, nausea, and fatigue are also common. |
Toxicology CRS | N/A | N/A | N/A |
Clinical Safety signal | Boxed warning for serious skin reactions including SJS/TEN. Hyperglycemia, peripheral neuropathy, ocular surface toxicity, and pneumonitis also require monitoring. | Stomatitis, dry eye and keratitis, nausea, and alopecia. Interstitial lung disease is a class warning for DXd conjugates and requires prompt steroid intervention. | Boxed warning for ocular toxicity — keratopathy, blurred vision, and dry eye. Peripheral neuropathy, nausea, and fatigue are also common. |
Clinical Selected reported efficacy | ORR 67.7% | ORR 79% | ORR 52% |
Clinical Reported ORR | 67.7% (EV + pembrolizumab) | 74% | 100% |
Clinical Reported PFS | 12.5 mo vs 6.3 mo (chemo) | 4.4 | 13.49 |
Clinical Reported OS | 31.5 mo vs 16.1 mo (chemo) | 12.9 | — |
Clinical Result source | EV-302 / KEYNOTE-A39 (NCT04223856) | ClinicalTrials.gov NCT04656652 | ClinicalTrials.gov NCT02606305 |
Clinical Program phase | APPROVED | APPROVED | APPROVED |
Clinical Trial activity | No active/completed counts | No active/completed counts | No active/completed counts |
Clinical Trial ref | NCT04223856 | NCT04656652 | NCT02606305 |
Preclinical Animal (cat.) | Human, Mouse, In vitro | Mouse, In vitro | Human, Mouse, Rat, In vitro |
추천 비교
추천 비교